INTRODUCTION
============

It is currently thought that the dementia of Alzheimer's disease is due to the neurotoxicity of the deposits or aggregates of amyloid-β (Aβ) in the extracellular space of the cerebral cortex. In support of this model various familial forms of the disease are characterized by the early deposition of plaque and the development of dementia. In light of the similar pathology observed between the familial forms and the sporadic disease, many workers have developed transgenic mouse models in which the animals were transfected with mutant forms of the amyloid precursor protein (APP) and/or presenilins 1 and 2. The APP normally is cleaved to form two growth factors, αsAPP and βsAPP while the presenilins are components of the γ secretase which clips the Aβ from the membrane. The αsAPP is fifty times more active than βsAPP's ([@B20]), but the latter is present at much higher concentrations in the brain ([@B11]).

Yet, a major philosophical problem with this approach is that the vast majority of the elderly with late onset disease do not have these mutations. In fact in genome wide association studies the most consistently observed genetic variants associated with the late onset disease are found in the apoE and clusterin genes. Furthermore, another difference between the late onset and familial forms is that in human studies [@B40] reported that the mRNA for APP was not elevated in late onset Alzheimer's disease, but was significantly higher in individuals with the various forms of the familial disease and Down's syndrome. Although western blotting of APP would be more definitive, when increases are seen in mRNAs they are commonly accepted as a measure of the total protein content. Hence, these data might suggest that one possible underlying biochemical defect seen in the familial forms of the disease may result in part from elevated levels of APP. Studies on the role of APP in cellular metabolism may give a clue as to how such elevations might lead to the early onset disease.

Knockout studies of APP have reported that this growth factor is necessary for normal neuronal development ([@B9]). Furthermore, studies by [@B38] have suggested that APP may play an important role at one particular stage in normal embryonic development. As the brain develops the embryo accumulates an excess of neurons and axons. These investigators reported that APP activates death receptor 6 which leads to axon pruning and apoptosis of the excess neurons. These data might suggest that the loss of cognition seen early in the familial forms of the disease before there is overt neuropathology could result from excessive axon pruning due to the high levels of APP; while later in the progression of the disease the high levels of APP could lead to increased neuronal apoptosis with the development of overt neurohistopathology.

Of greater concern there have been nine phase III clinical trials of agents that were effective in transgenic mice but failed to show any efficacy in patients with late onset disease (**Table [1](#T1){ref-type="table"}**).

###### 

Failed phase III trials of agents which were effective in transgenic mouse models.

      Drug                   Mechanism               Reference           Animal reference
  --- ---------------------- ----------------------- ------------------- -------------------
  1   Abeta vaccine          Clear abeta             [@B21]              [@B24] and [@B33]
  2   Tarenflurbil           γ-Secretase inhibitor   [@B17]              [@B27]
  3   Semagacestat           γ-Secretase inhibitor   [@B45]              [@B1]
  4   MK-677                 IGF-1 secretagogue      [@B46]              [@B7]
  5   *Ginkgo biloba*        Antioxidant             [@B10] and [@B50]   [@B49]
  6   Estrogen               Hormone replacement     [@B15]              [@B29] and [@B8]
  7   Docosahexaenoic acid   Omega-3 fatty acid      [@B41]              [@B6]
  8   Bapineuzumab           Monoclonal antibody     [@B43]              [@B23]
  9   Solanezumab            Monoclonal antibody     [@B12]              [@B23]

The probability of nine failures in nine trials for a presumed association is 2^9^ or 1 in 512 which gives a *p* = 0.0195.

Many have ascribed these failures to the initiation of therapy only after the subjects have exhibited significant cognitive decline. This was not true in two of these trials: the GEM (Ginkgo Evaluation of Memory) trial of *Ginkgo biloba* ([@B10]) and the Women's Health Initiative Trial of estrogen alone ([@B15]).

In the GEM trial of *G. biloba* the subjects were followed for 7 years ([@B10]). The investigators observed no difference in the incidence of dementia between the placebo and the *Ginkgo* treated subjects even though this agent was effective in transgenic mice (**Figure [2](#F2){ref-type="fig"}**; [@B49]).

Similarly, in the estrogen only arm of the Women's Health Initiative Trial the subjects were also followed for 7 years (**Figure [3](#F3){ref-type="fig"}**; [@B15]). After an initial improvement in cognitive scores which was probably due to a training effect, there were similar declines in the scores of the placebo and estrogen groups.

Furthermore, permanent damage to neurons, such as apoptosis and tangle deposits, is thought to only occur late in the disease. Hence, the late administration of effective agents should at least slow the cognitive decline, if not reverse the disease process. In fact in many of the transgenic mouse studies, elderly animals showed cognitive improvement when given some of these agents ([@B23]).

In all of these trials only solanezumab gave even the faintest hope of slowing this decline. But even this agent failed to meet the primary end points, and the noted benefit was only seen after combining the results of subjects with early disease in the two trials of the drug, suggesting that the effect may not have been sufficiently robust to be of clinical significance ([@B12]). The Food and Drug Administration (FDA) has refused to accept these findings as part of a future New Drug Application (NDA).

In spite of these failures the general thrust of drug development continues to seek new agents which will decrease the production of Aβ or enhance its clearance. These agents include new antibodies, vaccines, and γ-secretase inhibitors. Also a number of firms have developed inhibitors of the β-secretase (BACE1). This enzyme cleaves APP at the site which yields the Aβ peptide and the βsAPP (**Figure [1](#F1){ref-type="fig"}**). This would seem to be a somewhat hazardous approach for the long term treatment of patients with cognitive impairment, since knocking out BACE1 has been shown to lead to significant deficits in brain function ([@B28]; [@B22]; [@B42]). The most serious of these problems is that these animals have been reported to develop a seizure disorder associated with an increased density of surface Na~x~1.2 channels and increased intrinsic firing of isolated neurons and in hippocampal brain slices ([@B22]). In a short term phase I trial in normal volunteers the Merck BACE1 inhibitor, showed no adverse effects. But considering that these adverse effects may require long term administration, since it may dependent upon inducing the Na~x~1.2 channels, it may take months to observe this toxicity. Furthermore decreasing the level of Aβ in the brain may require higher doses than those used in the phase I trial. Hence, at higher doses for longer treatment periods there could be an increased risk for observing the toxic side effects.

![**Amino acid sequence of APP**.](fphar-04-00059-g001){#F1}

![**The effect of *Ginkgo biloba* on Cognitive Function in the GEM Trial (taken from [@B10])**.](fphar-04-00059-g002){#F2}

![**The effect of estrogen alone on Cognitive Function in the Women's Health Initiative (taken from [@B15])**.](fphar-04-00059-g003){#F3}

The only agent which has actually shown any promise of a viable treatment for Alzheimer's disease is methylene blue ([@B53]). This drug has been used as a urinary tract disinfectant and analgesic since the 1930s. Basic studies have demonstrated that its administration can lead to the loss of tangles, another pathological manifestation of Alzheimer's disease. Tangles result from cellular stress which leads to hyperphosphorylation of a neuronal, cytoskeletal protein, *tau* (P-*tau*). The P-*tau* then aggregates to form tangles. In a small phase II trial patients receiving 138 mg per day of the drug showed a markedly reduced cognitive decline during a 1 year study period. Yet, those receiving twice the dose showed a parallel decline to the placebo. A chemical modification of this agent is currently going into a phase III clinical trial. It will be interesting to see whether they can replicate their initial findings.

A NEW PARADIGM FOR THE ETIOLOGY OF THE DEMENTIA OF ALZHEIMER'S DISEASE
======================================================================

In light of these failures it would seem reasonable to examine new paradigms for the etiology of this dreaded condition. A number of years ago we asked the question:

Since Aβ is produced in everyone why is plaque only seen in the brains of the elderly?

We postulated that normally Aβ is bound to proteins which keep it in solution and thereby prevent plaque formation. And indeed this turned out to be the case! When we ran western blots of fresh or fresh frozen cerebrospinal fluid (CSF) on denaturing gels, we observed that there was only a single Aβ-immunoreactive band which was consistently found at around 62 kDa (**Figure [4](#F4){ref-type="fig"}**; [@B13]). And was associated with an endoplasmic reticulum (ER) chaperone, ERp57.

![**Western blots of human, CSF with antibodies to ERp57 and Aβ**.](fphar-04-00059-g004){#F4}

Furthermore, on immunopurification we were able to isolate the complex with antibodies to either Aβ or ERp57 (**Figure [5](#F5){ref-type="fig"}**).

![**Immunoopurification of the Aβ**-ERp57 Complex from Human CSF. Aβ and ERp57 were isolated by immunoprecipitation. The samples were then purified by western blotting on sodium docecyl sulfate-polylacrylamide gel electrophoresis. The bands were identified by antibodies to ERp57 **(A)** and Aβ **(B)**. (Taken from [@B13])](fphar-04-00059-g005){#F5}

A large number of studies on the biochemistry of the ER, posttranslational, protein processing pathway have reported that ERp57 binds to nascent proteins at *N*-glycosylation sites in association with another ER chaperone, calreticulin. In line with these observations, when the CSF was run on a native gel, the band moved to 118 kDa and was associated with both ERp57 and calreticulin (**Figure [6](#F6){ref-type="fig"}**).

![**Western blot of the Aβ--ERp57--calreticulin complex from human CSF after separation on a native gel (taken from [@B13]**).](fphar-04-00059-g006){#F6}

The fact that the Aβ and the two chaperones all shifted to this higher molecular weight along with the immunopurification data strongly supports our claim that the Aβ band is not either of the two sAPP's which have similar molecular weights.

Finally, since the Aβ found in plaque is only present as the naked peptide, one possibility is that the complex was originally in the plaque but broke down when it was solubilized by the usual treatment with either concentrated formic or trifluoroacetic acid. This is not likely to be the case since treatment of CSF under these same conditions had no effect on the complex (channels 3 and 4) (**Figure [7](#F7){ref-type="fig"}**).

![**Immunoblot of Aβ** in CSF after treatments to dissociate the Aβ--ERp57 complex. Channel 1 -- molecular weight markers; channel 2 -- untreated CSF; channel 3 -- CSF treated with 70% formic acid; channel 4 -- CSF treated with 80% trifluoroacetic acid; channel 5 -- CSF treated with 6 M guanidine isothiocyante; channel 6 -- CSF treated with 6 M urea; channel 7 -- CSF proteins which did not bind to a boronate column; channel 8 -- CSF proteins which bound to a boronate column; channel 9 -- treatment of the complex with glycine buffer, pH 9.0 (taken from [@B13]).](fphar-04-00059-g007){#F7}

Chaotropic agents such as urea and guanidine isothio- cyanate also had no effect on the complex (channel 5 and 6). In fact the only procedure which did affect the complex was storage overnight at 4°C in a pH 9.0 buffer (channel 9). The other interesting aspect of this study was that the complex bound to a bonate column, a synthetic lectin, suggesting that the Aβ is glycosylated (channel 8).

The binding of ERp57 to APP is not unique. Two plasma membrane receptors, the vasopressin receptor ([@B2]) and the 1,25 dihydroxy vitamin D plasma membrane receptor ([@B37]; [@B36]), have also been shown to have bound ERp57. The latter receptor is present in the plasma membrane of enterocytes and modulates Ca^++^ uptake from the intestines. The ERp57 would appear to have a role in signal transduction since knocking it down or inhibiting it with antibody to its terminal carboxy end inhibited 1,25 dihydroxy vitamin D stimulated Ca^++^ uptake ([@B37]; [@B36]). It should also be noted that the title of the publication by [@B2] demonstrating the binding of ERp57 to the vasopressin receptor is incorrect. When these workers originally cloned and sequenced ERp57, they erroneously identified it as a phosphatidylinositol specific phospholipase C ([@B3]). We found that the ERp57 purified from rat liver ([@B47]) and rERp57 generated using the authors' plasmid had no phospholipase activity ([@B48]) and instead it is a thiol:protein disulfide oxidoreductase: a family of enzymes that catalyzes both the oxidation and reduction of protein sulfur groups and is usually referred to as a Protein Disulfide Isomerase (PDI).

THE EFFECT OF AGE ON THE COMPONENTS OF THE ER, POSTTRANSLATIONAL, PROTEIN PROCESSING PATHWAY
============================================================================================

In light of these findings we hypothesized that the dementia seen in late onset Alzheimer's disease is due to a decline in the capacity of the neurons to catalyze the ER, posttranslational, protein processing of the synaptic membrane proteins that are necessary for a functioning memory ([@B13])! In support of this hypothesis we found that ERp57 does decline with age (**Figure [8](#F8){ref-type="fig"}**; [@B14]).

![**The effect of age on the ERp57 content of rat, hepatic microsomes (taken from [@B14]**).](fphar-04-00059-g008){#F8}

Several other ER chaperones showed similar declines (**Table [2](#T2){ref-type="table"}**).

###### 

Effect of age on the content of rat liver ER chaperones (taken from [@B14]).

  Chaperone      Peak concentration μg/mg protein   Concentration @ 874 days μg/mg protein   Constitutive decline %   Show cyclic variation   Cyclic variation % decline
  -------------- ---------------------------------- ---------------------------------------- ------------------------ ----------------------- ----------------------------
  BiP            80.0                               48.5                                     39                       Yes                     50
  Calnexin       57.4                               40.5                                     29                       No                      --
  Calreticulin   7.6                                4.8                                      8                        No                      --
  ERp55          34.8                               13.1                                     51                       Yes                     73
  ERp57          15.4                               8.2                                      32                       Yes                     71
  ERp72          141                                100                                      30                       No                      --
  Total          336.2                              215.1                                    37                                               

Finally, data from other laboratories would suggest that there is also a decline in the *N*-glycosylation pathway with age. Firstly, there is a reduced content of *N*-glycosylated proteins in the tissues of the elderly ([@B26]). Yet, this decline could be due to decreases in gene transcription. On the other hand, a number of studies have suggested that it may also be due to changes in the activity of the *N*-glycosylation pathway. This concept is based on the effect of age on the content of dolichol in various tissues, a necessary cofactor for *N*-glycosylation.

The initial step in the *N*-glycosylation pathway is the synthesis of an oligosaccharide bound to dolichol phosphate ([@B54]; [@B19]; [@B25]; **Figure [9](#F9){ref-type="fig"}**). Dolichol is a high molecular weight terpine which serves as a cofactor for the cytosolic synthesis of the oligosaccharide. Once the complex is fully synthesized, it is transferred to the lumen of the ER and attached to an ξ-amino group of an asparagine by an oligosaccharide transferase (OST; [@B25]). The addition of the individual sugars to the carbohydrate complex is catalyzed by a family of specific monosaccharide transferases (MST; [@B54]; [@B19]; [@B25]). The first sugars added to the dolichol phosphate are a pair of *N*-acetylglucosamines, followed by nine mannoses and three glucoses. A large number of studies have shown that as animals age there is a 5--10-fold increase in the cellular content of both dolichol and dolichol phosphate (for example see [@B30]). Since there is no increase in the synthesis of dolichol, this finding is consistent with a blockage of the addition of the first *N*-acetylglucosamine. And indeed it has been reported that the activity of ALG7, the MST that adds the first N-acetylglucosamine to the dolichol phosphate, does decline with age ([@B35]).

![**The *N*-glycosylation pathway ([@B19])**.](fphar-04-00059-g009){#F9}

OUR STUDIES INDICATE THAT
=========================

1.  The Aβ-chaperone complex is formed during the normal processing of APP in the lumen of the ER.

2.  If this complex is not produced, then the naked peptide is secreted and precipitates on its release from the cell to form plaque.

3.  On western blotting of a native gel we found that the complex contains two ER chaperones, ERp57 and calreticulin.

4.  In the CSF Aβ is probably also *N*-glycosylated.

5.  These data indicate that plaque formation is due to a decline in the capacity of the ER to catalyze the posttranslational processing of APP. It may also account for many other manifestations of aging.

6.  Forty percentage of the proteins synthesized in the cell undergo this same posttranslational processing in the ER, including all the synaptic membrane proteins that are necessary for a functioning memory.

7.  With age there is a decrease in the components of the ER, protein, posttranslational processing pathway.

THE ROLE OF DECREASED ER, PROTEIN, POSTTRANSLATIONAL PROCESSING IN THE DECLINE WITH AGE IN MITOCHONDRIAL FUNCTION AND MYELIN CONTENT
====================================================================================================================================

There are numerous phenomena associated with the aging process. Two of the most fundamental are the decline with age in mitochondrial function and myelin content. One of the major problems with the Aβ model is that it does not address what the relationship of either of these two well-documented processes has to do with plaque deposition. I feel that both of these processes may be related to the decline in ER function.

THE ROLE OF THE LOSS OF ER FUNCTION IN THE DECLINE IN MITOCHONDRIAL FUNCTION
----------------------------------------------------------------------------

It is well-known that as mitochondria age they acquire structural defects ([@B4]). The damaged mitochondria are cleared from the cell by autophagy. Many of the proteins which make up the autophagic vacuoles are processed in the ER and *golgi* ([@B32]). Hence, with a decline in ER function there is also a decline in autophagy. Such declines have been associated with the onset of some age related neurodegenerative diseases ([@B39]).

Second, the mitochondria are directly bound to the ER through the mitochondrial associated membrane (MAM; [@B31]; [@B18]; [@B44]). This structure serves three, major functions. The first is to transport critical phospholipids from the ER, where they are synthesized, into the mitochondria where they serve vital roles in the maintenance of the structure and function of the mitochondria. Further, it regulates Ca^++^ homeostasis in the mitochondria and thereby oxidative phosphorylation.

A final role for the ER in maintaining mitochondrial structure and function is the control of mitochondrial fission and fusion. As defective mitochondria are cleared by autophagy, they are replaced through a process involving both mitochondrial fission and fusion. Recent studies have indicated that several proteins in the MAM play major roles in both of these processes ([@B31]; [@B16]). In particular two critical proteins which tether the ER to the mitochondrial outer membrane are mitofusin 1 and 2 (*mfn1* and *2*; [@B31]; **Figure [10](#F10){ref-type="fig"}**). These transmembrane proteins are located in both the ER membrane and the outer membrane of the mitochondria. Both *mfn1* and*2* undergo posttranslational processing in the ER. Hence, a decline in the capacity of the ER to catalyze their posttranslational processing would be expected to have a profound effect on mitochondrial structure and function. Such declines in ER function could compromise the ability of the cell to maintain metabolically active mitochondria.

![**The tethering of the ER to the mitochondria (taken from [@B31])**.](fphar-04-00059-g010){#F10}

THE ROLE OF THE LOSS OF ER FUNCTION IN THE DECREASE IN MYELIN WITH AGE
----------------------------------------------------------------------

Finally, the myelin sheaths are the plasma membranes of oligodendrocytes and Schwann cells (**Figure [11](#F11){ref-type="fig"}**). This structure is also processed in the ER. The observed decline seen with age in the capacity of the ER to catalyze this processing could explain the loss of white matter consistently seen in the elderly and the slowing of thought processes as we age.

![**Schwann cell**.](fphar-04-00059-g011){#F11}

PROPOSED CELLULAR AND ANIMAL MODELS FOR DRUG DISCOVERY
======================================================

These findings would suggest that we should be seeking agents for the treatment of Alzheimer's disease that enhance the components of the ER, posttranslational, protein processing pathway. Classically the usual procedure for such a search has been to construct test systems in which the promoter region for the target protein is linked to a reporter system, such as luciferase, a beta galactosidase or a fluorescent protein. Yet, we now know that non-coding regions of the DNA and histone modifications play major roles in controlling both transcription and translation of proteins. Hence, potentially the most fruitful approach for high-throughput drug screening would be to develop cell models in which compact fluorescent proteins, such as green fluorescent protein (GFP), are embedded in an exon of the otherwise intact target gene. This should maximize the number of potential target sites for small molecule, drug discovery.

Such transgenic models are created in embryonic or induced pluripotent stem cells by homologous recombination using a variety of site specific endonuclease systems. These models are usually created with either mouse or human embryonic or induced pluripotent stem cells. In the case of the mouse lines it would also be possible to clone the cells and create transgenic, adult animals. This is an important step since it is necessary to demonstrate that the insertion of the fluorescent protein does not lead to an animal with compromised metabolism. Usually the indicator system is inserted in either the first or last exon of the native protein. If these turn out to produce metabolically compromised cells, then it would be necessary to insert the indicator in an exon that does not compromise metabolic function. The stem cells can then be transformed into a variety of tissue types by incubating with the appropriate growth factors. With the construction of the labeled cell lines, they can be used to automatically screen large libraries of compounds in microtiter plate readers.

Similarly intact animals models could be developed in which the relevant proteins have been knocked down. It is necessary to only knock them down because knockouts of the chaperones and components of the *N*-glycosylation pathway are lethal mutants. The possible approaches could include a lox-cre system in which the specific tissue cell type, such as neuronal cells have a haploid knock out of the critical gene. Alternatively, it is possible to develop models with a global knock down of the target gene(s) with synthetic, antisense oligonucleotides.

In an unrelated study of the toxicity of methoxychlor, we observed that feeding this insecticide to rats for 3 weeks specifically increased the levels of ERp57 in hepatic microsomes (ER) (**Figure [12](#F12){ref-type="fig"}**).

![**The effect of feeding of methoxychlor for 3 weeks on the hepatic level of ERp57 (data taken from [@B34])**.](fphar-04-00059-g012){#F12}

CONCLUSION
==========

1.  Nine phase III clinical trials of agents that were effective in transgenic mice were not effective in patients with late onset dementia.

2.  The reason that plaque does not form in the young is because Aβ is normally *N*-glycosylated and bound to two ER chaperones, ERp57 and calreticulin, which keep it in solution.

3.  These components decline with age.

4.  These findings suggest that the dementia seen in late onset Alzheimer's disease is due to a decline in the ER, posttranslational processing of the synaptic, membrane proteins that are necessary for a functioning memory.

5.  It also suggests that the loss of mitochondrial function and white matter in the elderly is due to this decline in ER function.

6.  This paradigm suggests new cellular models for drug discovery in which fluorescent proteins are inserted into an exon of the various components of the ER, posttranslational, protein processing pathway.

7.  Animal models could be constructed in which the critical proteins are knocked down by standard procedures and then candidate drugs are administered to test whether they improve cognition.

IMPLICATIONS FOR FUTURE DRUG DISCOVERY TO TREAT ALZHEIMER'S DISEASE AND OTHER DISEASES ASSOCIATED WITH AGING
============================================================================================================

Finally, over the past two decades the pharmaceutical industry and funding agencies and foundations have made and are continuing to make massive investments in the search for disease modifying treatments for Alzheimer's disease and other diseases of the elderly. Although these efforts have taken a variety of approaches, the bulk have sought treatments based on the Aβ hypothesis that seek to improve cognitive function by decreasing the brain content of Aβ. Considering the number of these agents currently in the pipeline, it is clear that this approach will continue to dominate drug development for the foreseeable future. Yet, since many of these new agents are merely variations on earlier failed investigational drugs, there is a significant probability that they too will not prove to be efficacious in phase III clinical trials.

In view of the long, lag period between the initial identification of new targets and the final regulatory approval of agents developed on the basis of new paradigms, it would seem prudent at this point to consider other models for drug discovery in case the current batch of investigational drugs fail to fulfill their early promise. At the present time there is little chance that this lag period can be foreshortened by evaluating therapeutic efficacy based on surrogate measures, because changes in the levels of such measures have not been demonstrated to correlate with clinical efficacy. For example, the two most widely accepted biomarkers in the CSF of disease status are low levels of Aβ and high levels of P-*tau*. Yet in the recent failed bapineuzumab trial, P-*tau* levels did decline, but the patients still showed no clinical benefit ([@B5]).

Many have cited the experience in the treatment of hypertension in which demonstrating that decreasing blood pressure was sufficient grounds for drug approval. But this surrogate measure was based on clinical trial data that had shown that a decrease in blood pressure led to a pronounced decrease in morbid events ([@B51],[@B52]). In fact the decrease was so pronounced that in the present era of drug trials, a Data and Safety Monitoring Board would certainly have ended the 1970 trial no later than 3 years instead of continuing it for the full 5 years laid out in the original protocol. Until such robust surrogate measures have been identified or some agent does appear to show efficacy in phase III clinical trials which could thereby represent a template for future drug development, the most conservative approach would appear to be for industry to cast a wide net of potential targets for drug development rather than focusing on a single, possible culprit which has failed to lead to the development of effective agents.

Conflict of Interest Statement
==============================

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: *Yasong Lu, Bristol-Myers Squibb, USA*

[^2]: Reviewed by *Emanuela Esposito, University of Messina, Italy; David Riddell, Pfizer, USA*

[^3]: ^†^ Many of the concepts outlined in this presentation are covered by US and foreign patents while the cell and animal models are the subject of a provisional patent

[^4]: This article was submitted to Frontiers in Experimental Pharmacology and Drug Discovery, a specialty of Frontiers in Pharmacology.
